Products

Drug Discovery

The continuous rise in costs for pharmaceutical products and the threat of generics forces the industry to take a closer look at traditional workflows.

 

Polymorphism has become a focus in today’s pharmaceutical research laboratories s as it affects a number of issues in pharmaceutical systems varying from processing characteristics, shelf life and bioavailability. To secure potential product patents polymorph screening has been moved to a very early stage in the drug discovery process. 

 

Historically in the early stages of drug discovery, the focus was on the chemical effects, leaving the analysis of the physical effects using formulation and solubiliy studies as the last link in the process. This approach could lead to the terrible consequence of missing important properties required for dosage, solubility or storage. To avoid setbacks in the final development stage it is crucial to have already eliminated unsuitable compounds at an earlier stage using solubility and pre-formulation screening.

 

The main focus in research was on finding new drug candidates. However, pre-formulation screenings have shown that some do not work with the current formulation libraries, hence new formulations are required.

 

As the early discovery stage involves a large number of candidates with very small sample volumes to be tested, an automated system is required to cope with the requirements. Hence new workflows and hardware systems are required which enable the small volumes of material available at the early discovery stage to be dealt with, in order to study the physical and chemical properties.

 

 

Polymorphism & Crystallisation Screening

 

•  CRISSY® - Automation Platform for Polymorphism & Crystallisation Studies
  

 

Preformulation & Solubility Testing

 

•  SuSy - Pre-Formulation & Solubility Screening Workbench
  

 

Formulation Development

 

•  Formula X - Development Platform for New Formulations
  

 

Weighing Station

 

•  Calli® – weighing and dosing system